Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more
Market Cap & Net Worth: Humacyte Inc (HUMA)
Humacyte Inc (NASDAQ:HUMA) has a market capitalization of $204.58 Million ($204.58 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15977 globally and #6182 in its home market, demonstrating a -14.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Humacyte Inc's stock price $1.06 by its total outstanding shares 192996511 (193.00 Million).
Humacyte Inc Market Cap History: 2020 to 2026
Humacyte Inc's market capitalization history from 2020 to 2026. Data shows change from $1.96 Billion to $204.58 Million (-34.13% CAGR).
Index Memberships
Humacyte Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.01% | #424 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #1494 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.51 Trillion | 0.01% | #219 of 263 |
Weight: Humacyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Humacyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Humacyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
260.21x
Humacyte Inc's market cap is 260.21 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.96 Billion | $1.49 Million | -$66.52 Million | 1316.41x | N/A |
| 2021 | $1.40 Billion | $1.26 Million | -$26.48 Million | 1107.86x | N/A |
| 2022 | $407.22 Million | $1.56 Million | -$11.96 Million | 260.21x | N/A |
Competitor Companies of HUMA by Market Capitalization
Companies near Humacyte Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Humacyte Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Humacyte Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Humacyte Inc's market cap moved from $1.96 Billion to $ 204.58 Million, with a yearly change of -34.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $204.58 Million | +10.36% |
| 2025 | $185.37 Million | -80.98% |
| 2024 | $974.63 Million | +77.82% |
| 2023 | $548.11 Million | +34.60% |
| 2022 | $407.22 Million | -70.90% |
| 2021 | $1.40 Billion | -28.71% |
| 2020 | $1.96 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Humacyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $204.58 Million USD |
| MoneyControl | $204.58 Million USD |
| MarketWatch | $204.58 Million USD |
| marketcap.company | $204.58 Million USD |
| Reuters | $204.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.